German Multinational drug firm Fresenius Kabi, plans to invest up to €30 million in the next 2-3 years in doubling capacity of Dabur Pharma's active pharmaceutical ingredients manufacturing facility in Kolkata. Recently Fresenius Kabi, a unit of German drug maker Fresenius SE has completed acquisition of 90.9% stake in Dabur Pharma. Fresenius had acquired 73.27 % in Dabur Pharma from its promoters and certain other shareholders in April. Further, Fresenius made an open offer for an additional 20 % stake in the firm. The company also said it was looking to offload about one per cent stake in Dabur Pharma as per the necessary regulation of SEBI, for which it is in talks with different buyers. Dabur Pharma is focused on the global oncology market and its products are sold through its global footprint across 40 countries including the key markets of Europe and the US.